Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo
following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in
patients with NERD.